NEWS
By Lorraine Mirabella | June 24, 2009
The financially troubled developer of a huge business park being built at Aberdeen Proving Ground to serve base restructuring has backed out of the project and handed it off to Baltimore-based St. John Properties. Under plans approved by the Army, Rockville-based Opus East assigned development rights to St. John, which announced the agreement Tuesday and said it plans to start work on three or four research and office buildings. The 400-acre project, Government and Technology Enterprise, or GATE, is being developed as a 2 million- to 3 million-square-foot research and development park in partnership with the Army to handle growth from BRAC - military base restructuring.
NEWS
By Mary Gail Hare | December 14, 2008
The first building on the 400-acre research and development complex under development at Aberdeen Proving Ground has opened and is fully leased. Rockville-based Opus East, which is developing the Government and Technology Enterprise, or GATE, site in partnership with the Army, designed the $12 million structure to suit the needs of CACI International Inc., a technical consultant and federal contractor headquartered in Arlington, Va. The 60,000-square-foot structure...
NEWS
By Lorraine Mirabella | June 16, 2007
A Pittsburgh-based developer will build a hotel and conference center, offices and shops at Fort Detrick in Frederick County under an arrangement in which the U.S. Army donates 24 acres at the base in return for future development services. Detrick Properties LLC, a joint venture of Dick Corp. of Pittsburgh and Hunt Development Group, said yesterday that the Army selected it for the project through an agreement known as an "enhanced-use lease." The developers would be given the land to build the hotel and conference center and an undetermined amount of Class A office, technology and research space and shops, which the developer would lease to either government or private-sector tenants.
NEWS
By Tricia Bishop | October 1, 2006
About a dozen years ago, MedImmune Inc. - now the state's largest biotech business and among the top 10 in the world - nearly shut down. It had developed a respiratory treatment only to have the Food and Drug Administration reject it, and executives didn't have much in the way of a backup plan. Retooling a clinical trial eventually won FDA approval of the drug, but the lesson wasn't lost on executives: There is safety in numbers. For every 10 tries, only one drug makes it to market, which means there needs to be a long line of potential products in the wings for a company to continue.
NEWS
By JIM PUZZANGHERA | August 5, 2006
WASHINGTON -- The high-tech industry is furious that the Senate failed to extend a tax credit for research and development costs before departing yesterday for its monthlong summer recess. The credit, which saves U.S. companies about $7 billion a year by offsetting approximately 6 percent of their research and development expenses, expired Dec. 31. It's used heavily by high-tech firms as well as many traditional manufacturing companies. Business lobbyists have been pressing Congress to pass a retroactive extension so companies can accurately estimate their taxes and plan research initiatives.
NEWS
By NANCY JONES-BONBREST | May 24, 2006
Richard M. Ivey Worldwide vice president of research and development BD Diagnostics (a segment of Becton, Dickinson and Co.), Sparks Salary --$200,000 Age --49 Years on the job --23 How he got started --Ivey holds a bachelor's degree from Virginia Polytechnic Institute and a master's from George Washington University. An engineer by training, Ivey first worked in the nuclear power industry and later for a large plastics manufacturing firm. He started at BD as a manufacturing engineer, then went on to work as a design engineer and in program management before going into management of research and development.
NEWS
April 9, 2006
BSO requires strong board The Sun's editorial underscoring the significant management challenges facing the Baltimore Symphony Orchestra after its recent self-funded bailout is right on target but perpetuates a misconception about the role of a development director ("Intermezzo," April 2). The writer singles out that position as being the "key fundraiser." But that role may be better understood by an analogy to a sports team where the development director could be seen as the coach. A development director can only organize the plays and must depend upon the dedication and determination of the team and a commitment to sound organization from the front office.
NEWS
February 8, 2006
Allison blazes path to business future The investment by Allison Transmission, a division of General Motors, represents the future of manufacturing in Maryland ("New GM hybrid, new shot at jobs," Feb. 2). Innovation is the essence of today's business enterprise and the only way to stay competitive in manufacturing today. By thinking creatively and responding to the market with an innovative hybrid transmission, Allison has carved out a future in today's turbulent economic waters. With its high level of investment in research and development, Maryland has the best climate in the country for manufacturing innovation and new products.
NEWS
December 18, 2005
China's manufacturing cost advantage, growing research and development efforts and millions of science and engineering graduates are helping Beijing rapidly catch up with the United States' high-tech capabilities - posing not just an educational and economic challenge but also a potential military threat. Let's connect some of the dots: Almost half the states are doing a poor job setting high enough academic standards for science in their public schools, according to a report recently released by the Thomas B. Fordham Institute.
NEWS
By Tricia Bishop | June 12, 2005
Doug Doerfler says his Gaithersburg company has had to bag its flu-vaccine manufacturing project. Carol A. Nacy says her Rockville business might not be able to develop treatments for tuberculosis. And in Colorado, Kirk Christoffersen says an HIV vaccine his company was developing will have to be shelved because his corporation can't afford to proceed. "It's extremely costly" to find new cures and treatments, said Doerfler, chief executive officer of MaxCyte Inc., a 22-person company developing technology to help scientists work with cells.